New drug trial targets skin and scalp woes in down syndrome
NCT ID NCT07242638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or a type of hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin or scalp condition. The goal is to manage symptoms, not cure the disease, and participants may need to stay on the medication long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new pill help teens regrow hair lost to alopecia?
- Can a new biologic calm severe eczema?
- Can allergy and glaucoma drugs regrow hair when delivered by microneedling?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?